Introduction
Standard enterprise DCF analysis applies a single set of growth and margin assumptions to the entire company. For a pharma company, this approach is fundamentally flawed. A pharma company is not a single business with a unified growth trajectory; it is a portfolio of individual products, each with its own revenue curve, patent timeline, competitive landscape, and expected decline. A product generating $5 billion today might generate near-zero in four years due to loss of exclusivity. A pipeline asset generating nothing today might become a $3 billion product in five years, if it succeeds. Aggregating these radically different trajectories into a single revenue growth rate destroys the information that drives pharma valuation.
This is why sum-of-the-parts (SOTP) is the dominant methodology for valuing pharma companies in healthcare investment banking, equity research, and M&A advisory. SOTP builds the valuation from the bottom up, product by product, and then aggregates the pieces into a total enterprise value. Every healthcare banker must be able to build, explain, and defend a pharma SOTP.
The SOTP Framework
A pharma SOTP valuation has four components, each valued independently and then summed.
Commercial Product DCFs
Build individual revenue forecasts for each major commercial product, project through the LOE cliff, and discount to present value. This is the largest value component for Big Pharma.
Pipeline Asset Valuation
Apply risk-adjusted NPV (rNPV) to each pipeline asset, weighting expected cash flows by the probability of clinical and regulatory success at each phase gate.
Corporate Costs and Cash
Allocate unassigned corporate costs (G&A, corporate R&D not tied to specific products), add net cash or subtract net debt, and account for minority interests and other adjustments.
Sum and Cross-Check
Aggregate the three components to arrive at total equity value. Cross-check against trading multiples and precedent transactions to validate reasonableness.
Step 1: Commercial Product DCFs
For each major commercial product (typically those representing 5%+ of total revenue, though bankers sometimes model down to 2-3% contributors for completeness), build a standalone revenue forecast that captures the product's full lifecycle from current state through post-LOE decline.
Building the Revenue Forecast
Growth phase. Project revenue growth based on volume trends (new patient starts, line-of-therapy expansion, geographic launches in new markets) and pricing trends (net price changes after GTN deductions). Use physician survey data, weekly prescription (TRx) trends from IQVIA, competitive intelligence from clinical trial readouts, and management guidance to inform growth assumptions. The growth phase is where the most analytical judgment is required: will a drug maintain 10% annual growth for three more years, or will competitive entries cap growth at 5%? The answer depends on the competitive pipeline, payer dynamics, and treatment guideline evolution.
Peak/plateau phase. Identify the peak sales level and the duration of the plateau. Products in competitive categories may peak and begin declining even before LOE due to new market entrants. Keytruda, for example, may face competitive pressure from next-generation immuno-oncology combinations before its patent protection expires. Products in less competitive categories (orphan drugs, first-in-class mechanisms with limited pipeline competition) may sustain peak revenue for longer periods. The plateau duration directly affects the DCF because each additional year at peak revenue contributes meaningful present value.
LOE cliff. Model the revenue decline at loss of exclusivity. The cliff is the most consequential assumption in the product DCF:
| Drug Type | Cliff Severity | Cliff Timeline | Key Factors |
|---|---|---|---|
| Small molecule, competitive generic market | 80-90% revenue loss | 12-18 months | Multiple ANDA filers, Day 1 generic launch |
| Small molecule, limited generic interest | 60-75% revenue loss | 18-24 months | Fewer filers, complex formulation |
| Biologic, active biosimilar competition | 30-50% revenue loss | 3-5 years | Physician switching required, not auto-substituted |
| Biologic, limited biosimilar competition | 15-30% revenue loss | 3-5 years | Few biosimilar entrants, strong brand loyalty |
The cliff severity depends on lifecycle management effectiveness: patent thickets can delay generic entry, reformulations can retain some patients on the branded version, and authorized generics can capture a portion of the post-LOE market for the originator. Humira's US LOE illustrates the range of outcomes: despite biosimilar entry beginning in January 2023, AbbVie's extensive patent settlement agreements with biosimilar manufacturers (granting licenses on varying timelines) created a staggered, slower-than-expected erosion pattern rather than an overnight cliff.
Product-Level Margins and Cash Flows
Assign contribution margins to each product. Most pharma product DCFs use a contribution margin approach (revenue minus COGS and direct commercial expenses) rather than full EBITDA margins, because corporate overhead is allocated separately in Step 3. Contribution margins for major products typically range from 60-80%, varying by:
- COGS profile: Biologics have higher COGS (10-20% of revenue) than small molecules (5-10%) due to complex manufacturing
- Commercial intensity: Products requiring large sales forces (primary care drugs sold to thousands of physicians) have higher SG&A allocation than specialty drugs sold to a concentrated prescriber base
- Lifecycle stage: Mature products have lower commercial costs (marketing spend declines as the product is established) and higher contribution margins than recently launched products still in the investment phase
After contribution margin, estimate product-level taxes and capital expenditure requirements (typically minimal for individual products) to arrive at unlevered free cash flow per product per year. Discount at a standard pharma WACC of 8-10%.
- Terminal Value in Pharma Product DCF
Unlike a standard enterprise DCF where terminal value assumes perpetual growth and typically represents 60-80% of total value, a pharma product DCF typically has no terminal value (or a very small one representing post-LOE residual revenue). The product's revenue is projected through the patent cliff until it approaches zero or stabilizes at a residual level (typically 5-15% of peak for products with authorized generic strategies). This is a fundamental difference from enterprise DCF and is one of the key reasons SOTP is preferred for pharma: it explicitly captures the finite commercial life of each product rather than assuming perpetual growth at the company level. The absence of terminal value also means that the product DCF is less sensitive to long-term growth rate assumptions and more sensitive to near-term revenue trajectory and LOE timing.
Step 2: Pipeline Asset Valuation
Pipeline assets are valued using rNPV methodology, which projects the revenue and cash flows the asset would generate if approved, then discounts those cash flows by the cumulative probability of reaching approval from the asset's current development phase.
| Pipeline Phase | Typical PoS (Cumulative to Approval) | Valuation Approach |
|---|---|---|
| Preclinical | 5-10% | Often valued at cost or nominal value; too speculative for detailed rNPV |
| Phase I | 10-14% | rNPV with conservative peak sales; high uncertainty in market sizing |
| Phase II (pre-PoC) | 15-20% | rNPV with indication-specific assumptions; Phase II data pending |
| Phase II (post-PoC) | 25-40% | rNPV with data-informed assumptions; Phase II results available |
| Phase III | 50-65% | rNPV with detailed revenue model; clinical profile well-characterized |
| Filed/Pre-Approval | 80-90% | Near-commercial valuation; minimal remaining clinical risk |
For Big Pharma companies, the pipeline component typically represents 15-30% of total SOTP value, with the percentage higher for companies with strong late-stage pipelines (like AstraZeneca with its deep oncology pipeline) and lower for those dependent primarily on mature commercial products facing near-term LOE.
Key Pipeline Valuation Considerations
Therapeutic area-specific probability adjustments. Oncology assets use lower PoS (3-7% overall) than rare disease or hematology assets (20-25%). Using average PoS across all therapeutic areas will overvalue oncology pipeline and undervalue rare disease pipeline.
Competitive landscape adjustments. A pipeline asset entering a crowded market with multiple approved competitors warrants lower peak sales assumptions and potentially lower PoS (more competitive markets create higher bars for regulatory approval and commercial differentiation). A first-in-class asset targeting unmet need warrants higher assumptions.
Synergy with the existing portfolio. In an M&A context, the acquirer may apply higher PoS to pipeline assets if the acquirer's regulatory expertise, clinical trial infrastructure, or commercial capabilities meaningfully improve the development program's chance of success.
Step 3: Corporate Costs and Adjustments
After valuing individual products and pipeline assets, the SOTP must account for costs and items that are not captured in product-level analysis:
Corporate G&A (C-suite compensation, corporate office, investor relations, legal, finance, IT infrastructure) is typically projected as a flat annual amount or a percentage of total revenue, then discounted as a negative NPV. For a mid-size pharma company, corporate G&A might run $500 million-$1 billion annually; for Big Pharma, $2-4 billion.
Unallocated R&D includes early-stage research, discovery programs, platform investments, and exploratory programs that are not tied to specific pipeline assets in the SOTP. This spending is the "option value" of future pipeline generation. It is typically projected at the current run-rate and discounted as a negative NPV, though some analysts argue this understates its value because it ignores the future pipeline assets this spending will generate.
Net debt or net cash is added or subtracted at face value. For acquisition-heavy pharma companies, net debt can be substantial (AbbVie carried over $60 billion in debt after the Allergan acquisition). For cash-generative pharma companies with limited recent M&A, net cash positions of $10-30 billion are common.
Tax adjustments account for differences between statutory and effective tax rates, including the impact of IP-holding structures in low-tax jurisdictions (Ireland, Switzerland, Singapore, Puerto Rico). Many pharma companies have effective tax rates of 12-18%, significantly below the US statutory rate.
Minority interests and equity investments include stakes in other companies, joint venture interests, and unconsolidated subsidiaries. These are typically valued at market value (for publicly traded holdings) or book value (for private holdings) and added to the SOTP.
When to Use SOTP vs. Other Methodologies
SOTP is the primary methodology for pharma, but it is typically triangulated with other approaches to test reasonableness and provide context.
Enterprise DCF: Used as a cross-check, not as the primary method. Enterprise DCF can be useful for companies with highly diversified portfolios where individual product cliffs are offset by new launches (the "portfolio effect" creates a smoother aggregate revenue trajectory). However, even diversified pharma companies face periods where LOEs cluster, making enterprise DCF unreliable as a standalone methodology. Enterprise DCF is more appropriate for specialty pharma companies with largely genericized portfolios that have reached a post-cliff steady state.
[Comparable company analysis](/blog/how-to-build-comparable-company-analysis): EV/EBITDA multiples provide a market-based cross-check. However, pharma comparables must be carefully selected based on similar LOE profiles, revenue growth trajectories, pipeline quality, and therapeutic area mix. A company facing a major patent cliff in two years is not comparable to one with patent protection through 2035, even if both are "Big Pharma." The key adjustment metric is revenue durability: the percentage of current revenue that is protected by patents and exclusivity for the next 5+ years. Companies with higher revenue durability deserve premium multiples.
Precedent transactions: Pharma M&A transactions provide premium-adjusted benchmarks. Healthcare bankers analyze precedent deals based on the target's development stage, therapeutic area, competitive position, and LOE profile to derive applicable acquisition multiples. Key precedent metrics include EV/Revenue, EV/EBITDA, EV/Peak Sales (for pipeline assets), and the acquisition premium over unaffected trading price.
This SOTP framework is the foundation for understanding pharma financial analysis, M&A strategy, and the case studies that follow.
Free Interview PDF Guide